​

Grifols (GRFS) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChartTranscripts

Grifols Revenue Highlights

Latest Revenue (Y)

$6.59B

Latest Revenue (Q)

$1.63B

Main Segment (Y)

Haemoderivatives

Main Geography (Y)

USA and Canada

Grifols Revenue by Period

Grifols Revenue by Year

DateRevenueChange
2023-12-31$6.59B8.71%
2022-12-31$6.06B22.92%
2021-12-31$4.93B-7.62%
2020-12-31$5.34B4.73%
2019-12-31$5.10B13.64%
2018-12-31$4.49B3.91%
2017-12-31$4.32B6.62%
2016-12-31$4.05B2.93%
2015-12-31$3.93B17.26%
2014-12-31$3.36B22.38%
2013-12-31$2.74B4.61%
2012-12-31$2.62B45.96%
2011-12-31$1.80B81.24%
2010-12-31$990.73M8.49%
2009-12-31$913.19M12.14%
2008-12-31$814.31M15.79%
2007-12-31$703.29M8.40%
2006-12-31$648.80M23.75%
2005-12-31$524.28M-

Grifols generated $6.59B in revenue during NA 2023, up 8.71% compared to the previous quarter, and up 146.92% compared to the same period a year ago.

Grifols Revenue by Quarter

DateRevenueChange
2024-03-31$1.63B-8.13%
2023-12-31$1.77B10.77%
2023-09-30$1.60B-3.97%
2023-06-30$1.66B7.83%
2023-03-31$1.54B-9.93%
2022-12-31$1.71B11.14%
2022-09-30$1.54B-0.11%
2022-06-30$1.54B21.76%
2022-03-31$1.27B5.75%
2021-12-31$1.20B-
2021-09-30$1.20B-11.37%
2021-06-30$1.35B14.11%
2021-03-31$1.18B-9.52%
2020-12-31$1.31B-3.25%
2020-09-30$1.35B-2.21%
2020-06-30$1.38B7.01%
2020-03-31$1.29B-4.97%
2019-12-31$1.36B3.54%
2019-09-30$1.31B3.78%
2019-06-30$1.27B9.49%
2019-03-31$1.16B-5.40%
2018-12-31$1.22B6.91%
2018-09-30$1.14B4.26%
2018-06-30$1.10B7.24%
2018-03-31$1.02B-4.20%
2017-12-31$1.07B0.96%
2017-09-30$1.06B-6.46%
2017-06-30$1.13B6.51%
2017-03-31$1.06B-3.32%
2016-12-31$1.10B9.81%
2016-09-30$1.00B0.74%
2016-06-30$992.71M3.52%
2016-03-31$958.93M-9.77%
2015-12-31$1.06B9.43%
2015-09-30$971.20M-2.11%
2015-06-30$992.18M9.22%
2015-03-31$908.38M-0.97%
2014-12-31$917.29M10.88%
2014-09-30$827.31M1.79%
2014-06-30$812.78M16.92%
2013-12-31$695.17M4.42%
2013-09-30$665.72M-4.51%
2013-06-30$697.14M5.40%
2012-12-31$661.43M2.90%
2012-09-30$642.81M-1.11%
2012-06-30$650.02M10.16%
2011-12-31$590.07M3.49%
2011-09-30$570.20M52.50%
2011-06-30$373.91M48.43%
2010-12-31$251.91M30.44%
2010-09-30$193.12M-

Grifols generated $1.63B in revenue during Q1 2024, up -8.13% compared to the previous quarter, and up 94.92% compared to the same period a year ago.

Grifols Revenue Breakdown

Grifols Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Other Product$203.45M$250.16M$39.62M--
Other diagnostic$21.79M$21.74M$23.63M--
Transfusional medicine$648.48M$640.60M$712.24M--
Bio supplies$159.96M$146.08M$225.76M--
Haemoderivatives$5.56B$5.01B$3.81B$4.24B$3.99B
Fluid therapy and nutrition--$46.67M--
Hospital supplies--$70.22M--
Bio Supplies Product---$224.09M$266.54M
Transfusional Medicine---$714.16M$680.77M
Others Product---$31.99M$22.82M
Other Diagnostic---$27.63M$19.94M
Hospital Supplies---$58.30M$67.49M
Fluid Therapy And Nutrition---$41.36M$47.68M

Grifols's latest annual revenue breakdown by segment (product or service), as of Dec 23: Haemoderivatives (84.32%), Transfusional medicine (9.84%), Other Product (3.09%), Bio supplies (2.43%), and Other diagnostic (0.33%).

Grifols Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
European Union$893.05M$711.58M$544.04M--
USA and Canada$3.90B$3.86B$3.15B--
Spain$362.88M$320.63M$362.41M--
Rest of the world$1.44B$1.18B$872.12M--
Country Of Domicile---$339.17M$268.29M
United States And Canada---$3.60B$3.39B
Rest Of World---$905.80M$851.22M
European Union Excluding Spain---$495.32M$588.38M

Grifols's latest annual revenue breakdown by geography, as of Dec 23: USA and Canada (59.15%), Rest of the world (21.80%), European Union (13.55%), and Spain (5.50%).

Grifols Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MRKMerck$60.12B$16.66B
NVSNovartis$46.66B$11.83B
AZNAstraZeneca$45.81B$12.68B
BMYBristol-Myers Squibb Company$45.01B$11.89B
SNYSanofi$43.07B$11.12B
GSKGSK$30.33B$7.36B
AMGNAmgen$28.19B$8.50B
GILDGilead Sciences$27.12B$7.55B
BIIBBiogen$9.84B$2.47B
GRFSGrifols$6.59B$1.63B

GRFS Revenue FAQ

What is Grifols’s yearly revenue?

Grifols's yearly revenue for 2023 was $6.59B, representing an increase of 8.71% compared to 2022. The company's yearly revenue for 2022 was $6.06B, representing an increase of 22.92% compared to 2021. GRFS's yearly revenue for 2021 was $4.93B, representing a decrease of -7.62% compared to 2020.

What is Grifols’s quarterly revenue?

Grifols's quarterly revenue for Q1 2024 was $1.63B, a -8.13% decrease from the previous quarter (Q4 2023), and a 5.38% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.77B, a 10.77% increase from the previous quarter (Q3 2023), and a 3.32% increase year-over-year (Q4 2022). GRFS's quarterly revenue for Q3 2023 was $1.6B, a -3.97% decrease from the previous quarter (Q2 2023), and a 3.66% increase year-over-year (Q3 2022).

What is Grifols’s revenue growth rate?

Grifols's revenue growth rate for the last 3 years (2021-2023) was 33.63%, and for the last 5 years (2019-2023) was 29.29%.

What are Grifols’s revenue streams?

Grifols's revenue streams in c 23 are Other Product, Other diagnostic, Transfusional medicine, Bio supplies, and Haemoderivatives. Other Product generated $203.45M in revenue, accounting 3.09% of the company's total revenue, down -18.67% year-over-year. Other diagnostic generated $21.79M in revenue, accounting 0.33% of the company's total revenue, up 0.23% year-over-year. Transfusional medicine generated $648.48M in revenue, accounting 9.84% of the company's total revenue, up 1.23% year-over-year. Bio supplies generated $159.96M in revenue, accounting 2.43% of the company's total revenue, up 9.50% year-over-year. Haemoderivatives generated $5.56B in revenue, accounting 84.32% of the company's total revenue, up 11.05% year-over-year.

What is Grifols’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Grifols was Haemoderivatives. This segment made a revenue of $5.56B, representing 84.32% of the company's total revenue.